drugset / Trial / NCT04062357

Effectiveness and Tolerability of Lidocaine 5% Spray in Treatment of Lifelong Premature Ejaculation Patients.

NCT04062357

Phase 2 Completed 150 enrolled Sohag University
RandomizedParallel-groupSingle-blindTreatment

Summary

This study aimed to appraise effectiveness and tolerability of lidocaine 5% spray in treatment of patients with premature ejaculation (PE). The current study has been designed as a randomized single-blind placebo-controlled clinical trial. It was done on 150 lifelong PE patients with normal erection. They were randomized evenly categorized into two treatment groups. Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks. Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.

Timeline

Start
2018-04-20
Primary completion
2019-01-20
Completion
2019-04-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 5 mg Topical
Comparator Lidocaine Other / unclassified 10 mg Topical

Indications

No indication recorded.